Fc receptor but not complement binding is important in antibody protection against HIV
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
Richman, D. D., Wrin, T., Little, S. J., & Petropoulos, C. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630530100 · Cited by 1,200
Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal Antibody
Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren, P. W. H. I., Sawyer, L. S. W., Hendry, R. M., Dunlop, N., Nara, P. L., et al. (1994) · Science · doi:10.1126/science.7973652 · Cited by 1,100
Self-citationFcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Structural definition of a conserved neutralization epitope on HIV-1 gp120
Zhou, T., Xu, L., Dey, B., Hessell, A. J., Van Ryk, D., Xiang, S.-H., Yang, X., Zhang, M.-Y., Zwick, M. B., Arthos, J., et al. (2007) · Nature · doi:10.1038/nature05580 · Cited by 770
Self-citationBinley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappey, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.23.13232-13252.2004 · Cited by 705
Self-citationParren, P. W. H. I., Marx, P. A., Hessell, A. J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J. P., & Burton, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.17.8340-8347.2001 · Cited by 662
Self-citationAntibodies, viruses and vaccines
Burton, D. R. (2002) · Nature Reviews Immunology · doi:10.1038/nri891 · Cited by 637
Self-citationProgesterone implants enhance SIV vaginal transmission and early virus load
Marx, P. A., Spira, A. I., Gettie, A., Dailey, P. J., Veazey, R. S., Lackner, A. A., Mahoney, C. J., Miller, C. J., Claypool, L. E., Ho, D. D., et al. (1996) · Nature Medicine · doi:10.1038/nm1096-1084 · Cited by 465
Self-citationVeazey, R. S., Shattock, R. J., Pope, M., Kirijan, J. C., Jones, J., Hu, Q., Ketas, T., Marx, P. A., Klasse, P. J., Burton, D. R., et al. (2003) · Nature Medicine · doi:10.1038/nm833 · Cited by 460
Self-citationDistinct Pathogenic Sequela in Rhesus Macaques Infected with CCR5 or CXCR4 Utilizing SHIVs
Harouse, J. M., Gettie, A., Tan, R. C. H., Blanchard, J., & Cheng-Mayer, C. (1999) · Science · doi:10.1126/science.284.5415.816 · Cited by 320
Cited by
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203
The immune response during acute HIV-1 infection: clues for vaccine development
McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N., & Haynes, B. F. (2010) · Nature Reviews Immunology · doi:10.1038/nri2674 · Cited by 871
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection
Stettler, K., Beltramello, M., Espinosa, D. A., Graham, V., Cassotta, A., Bianchi, S., Vanzetta, F., Minola, A., Jaconi, S., Mele, F., et al. (2016) · Science · doi:10.1126/science.aaf8505 · Cited by 758
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
From Vaccines to Memory and Back
Sallusto, F., Lanzavecchia, A., Araki, K., & Ahmed, R. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.008 · Cited by 637
Tomaras, G. D., Yates, N. L., Liu, P., Qin, L., Fouda, G. G., Chavez, L. L., Decamp, A. C., Parks, R. J., Ashley, V. C., Lucas, J. T., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01708-08 · Cited by 631
Self-citationThe role of IgG Fc receptors in antibody-dependent enhancement
Bournazos, S., Gupta, A., & Ravetch, J. V. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00410-0 · Cited by 617
Beltramello, M., Williams, K. L., Simmons, C. P., Macagno, A., Simonelli, L., Quyen, N. T. H., Sukupolvi-Petty, S., Navarro-Sanchez, E., Young, P. R., de Silva, A. M., et al. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.08.007 · Cited by 592
Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design
Burton, D. R., & Hangartner, L. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055515 · Cited by 583
Self-citationA Functional Role for Antibodies in Tuberculosis
Lu, L. L., Chung, A. W., Rosebrock, T. R., Ghebremichael, M., Yu, W. H., Grace, P. S., Schoen, M. K., Tafesse, F., Martin, C., Leung, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.072 · Cited by 571
Hessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. H. I., Marx, P. A., & Burton, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1974 · Cited by 546
Self-citationStructural basis of potent Zika–dengue virus antibody cross-neutralization
Barba-Spaeth, G., Dejnirattisai, W., Rouvinski, A., Vaney, M.-C., Medits, I., Sharma, A., Simon-Lorière, E., Sakuntabhai, A., Cao-Lormeau, V.-M., Haouz, A., et al. (2016) · Nature · doi:10.1038/nature18938 · Cited by 533
Type I and type II Fc receptors regulate innate and adaptive immunity
Pincetic, A., Bournazos, S., DiLillo, D. J., Maamary, J., Wang, T. T., Dahan, R., Fiebiger, B.-M., & Ravetch, J. V. (2014) · Nature Immunology · doi:10.1038/ni.2939 · Cited by 514
Hessell, A. J., Rakasz, E. G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D. N., Koff, W. C., Watkins, D. I., & Burton, D. R. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000433 · Cited by 497
Self-citationBroadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Bournazos, S., Klein, F., Pietzsch, J., Seaman, M. S., Nussenzweig, M. C., & Ravetch, J. V. (2014) · Cell · doi:10.1016/j.cell.2014.08.023 · Cited by 493
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E. F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T. Y., et al. (2017) · Nature Medicine · doi:10.1038/nm.4268 · Cited by 487
B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study
Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2197 · Cited by 486
Broadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Moldt, B., Rakasz, E. G., Schultz, N., Chan-Hui, P.-Y., Swiderek, K., Weisgrau, K. L., Piaskowski, S. M., Bergman, Z., Watkins, D. I., Poignard, P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1214785109 · Cited by 463
Self-citationA robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
Ackerman, M. E., Moldt, B., Wyatt, R. T., Dugast, A.-S., McAndrew, E., Tsoukas, S., Jost, S., Berger, C. T., Sciaranghella, G., Liu, Q., et al. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.12.016 · Cited by 450
Self-citationCorti, D., Suguitan, A. L., Pinna, D., Silacci, C., Fernandez-Rodriguez, B. M., Vanzetta, F., Santos, C., Luke, C. J., Torres-Velez, F. J., Temperton, N. J., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41902 · Cited by 437
Corti, D., Langedijk, J. P. M., Hinz, A., Seaman, M. S., Vanzetta, F., Fernandez-Rodriguez, B. M., Silacci, C., Pinna, D., Jarrossay, D., Balla-Jhagjhoorsingh, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008805 · Cited by 426
Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice
Sapparapu, G., Fernandez, E., Kose, N., Cao, B., Fox, J. M., Bombardi, R. G., Zhao, H., Nelson, C. A., Bryan, A. L., Barnes, T., et al. (2016) · Nature · doi:10.1038/nature20564 · Cited by 408
The Role of Antibodies in HIV Vaccines
Mascola, J. R., & Montefiori, D. C. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101256 · Cited by 388
Antibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385
Self-citationEnhanced neonatal Fc receptor function improves protection against primate SHIV infection
Ko, S.-Y., Pegu, A., Rudicell, R. S., Yang, Z.-Y., Joyce, M. G., Chen, X., Wang, K., Bao, S., Kraemer, T. D., Rath, T., et al. (2014) · Nature · doi:10.1038/nature13612 · Cited by 384
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 383
Halper-Stromberg, A., Lu, C.-L., Klein, F., Horwitz, J. A., Bournazos, S., Nogueira, L., Eisenreich, T. R., Liu, C., Gazumyan, A., Schaefer, U., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.043 · Cited by 381
Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design
Diskin, R., Scheid, J. F., Marcovecchio, P. M., West, A. P., Klein, F., Gao, H., Gnanapragasam, P. N. P., Abadir, A., Seaman, M. S., Nussenzweig, M. C., et al. (2011) · Science · doi:10.1126/science.1213782 · Cited by 375
Winkler, E. S., Gilchuk, P., Yu, J., Bailey, A. L., Chen, R. E., Chong, Z., Zost, S. J., Jang, H., Huang, Y., Allen, J. D., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.026 · Cited by 366
Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology
Chung, A. W., Kumar, M. P., Arnold, K. B., Yu, W. H., Schoen, M. K., Dunphy, L. J., Suscovich, T. J., Frahm, N., Linde, C., Mahan, A. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.027 · Cited by 352
Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo
Lu, C.-L., Murakowski, D. K., Bournazos, S., Schoofs, T., Sarkar, D., Halper-Stromberg, A., Horwitz, J. A., Nogueira, L., Golijanin, J., Gazumyan, A., et al. (2016) · Science · doi:10.1126/science.aaf1279 · Cited by 347
Lambotte, O., Ferrari, G., Moog, C., Yates, N. L., Liao, H.-X., Parks, R. J., Hicks, C. B., Owzar, K., Tomaras, G. D., Montefiori, D. C., et al. (2009) · AIDS · doi:10.1097/qad.0b013e328329f97d · Cited by 342
Animal models for HIV/AIDS research
Hatziioannou, T., & Evans, D. T. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2911 · Cited by 340
El Bakkouri, K., Descamps, F., De Filette, M., Smet, A., Festjens, E., Birkett, A., Van Rooijen, N., Verbeek, S., Fiers, W., & Saelens, X. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0902147 · Cited by 335
Circulating and intrahepatic antiviral B cells are defective in hepatitis B
Burton, A. R., Pallett, L. J., McCoy, L. E., Suveizdyte, K., Amin, O. E., Swadling, L., Alberts, E., Davidson, B. R., Kennedy, P. T. F., Gill, U. S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121960 · Cited by 330
Shaw, G. M., & Hunter, E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006965 · Cited by 326
Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767749 · Cited by 323
The Immunoregulatory Roles of Antibody Glycosylation
Jennewein, M. F., & Alter, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.02.004 · Cited by 323
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Johnson, P. R., Schnepp, B. C., Zhang, J., Connell, M. J., Greene, S. M., Yuste, E., Desrosiers, R. C., & Reed Clark, K. (2009) · Nature Medicine · doi:10.1038/nm.1967 · Cited by 310
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., & Wang, L.-X. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3051266 · Cited by 308
Mouse model recapitulating human Fcγ receptor structural and functional diversity
Smith, P., DiLillo, D. J., Bournazos, S., Li, F., & Ravetch, J. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203954109 · Cited by 307
Boyle, M. J., Reiling, L., Feng, G., Langer, C., Osier, F. H., Aspeling-Jones, H., Cheng, Y. S., Stubbs, J., Tetteh, K. K. A., Conway, D. J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.012 · Cited by 306
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Self-citationIrani, V., Guy, A. J., Andrew, D., Beeson, J. G., Ramsland, P. A., & Richards, J. S. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.03.255 · Cited by 288
The growth and potential of human antiviral monoclonal antibody therapeutics
Marasco, W. A., & Sui, J. (2007) · Nature Biotechnology · doi:10.1038/nbt1363 · Cited by 284
Montefiori, D. C., Karnasuta, C., Huang, Y., Ahmed, H., Gilbert, P., de Souza, M. S., McLinden, R., Tovanabutra, S., Laurence-Chenine, A., Sanders-Buell, E., et al. (2012) · Journal of Infectious Diseases · doi:10.1093/infdis/jis367 · Cited by 284
Rudicell, R. S., Kwon, Y. D., Ko, S.-Y., Pegu, A., Louder, M. K., Georgiev, I. S., Wu, X., Zhu, J., Boyington, J. C., Chen, X., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02213-14 · Cited by 282
Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease
van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281
Elimination of HIV-1-infected cells by broadly neutralizing antibodies
Bruel, T., Guivel-Benhassine, F., Amraoui, S., Malbec, M., Richard, L., Bourdic, K., Donahue, D. A., Lorin, V., Casartelli, N., Noël, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms10844 · Cited by 271
Induction of Immunity to Human Immunodeficiency Virus Type-1 by Vaccination
McElrath, M. J., & Haynes, B. F. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.011 · Cited by 270
The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design
Rey, F. A., Stiasny, K., Vaney, M., Dellarole, M., & Heinz, F. X. (2018) · EMBO reports · doi:10.15252/embr.201745302 · Cited by 259
Burton, D. R., Hessell, A. J., Keele, B. F., Klasse, P. J., Ketas, T. A., Moldt, B., Dunlop, D. C., Poignard, P., Doyle, L. A., Cavacini, L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103012108 · Cited by 255
Self-citationNonhuman primate models of human viral infections
Estes, J. D., Wong, S. W., & Brenchley, J. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0005-7 · Cited by 255
Montero, M., van Houten, N. E., Wang, X., & Scott, J. K. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00020-07 · Cited by 253
Ferrari, G., Pollara, J., Kozink, D., Harms, T., Drinker, M., Freel, S., Moody, M. A., Alam, S. M., Tomaras, G. D., Ochsenbauer, C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00171-11 · Cited by 233
“The mechanism of protection was related, at least in part, to ADCC- and ADCVImediating antibodies (11, 13, 16, 17, 35).”
BackgroundUnravelling the mechanisms of durable control of HIV-1
Walker, B. D., & Yu, X. G. (2013) · Nature Reviews Immunology · doi:10.1038/nri3478 · Cited by 233
Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses
Tay, M. Z., Wiehe, K., & Pollara, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00332 · Cited by 229
“In non-human primate (NHP) passive immunization studies, with both high and low dose vaginal challenge of rhesus macaques with SHIV162p3, protection decreased by about 50% when the administered passive antibody was incapable of binding Fc receptors (105, 106).”
BackgroundLi, H., Wang, S., Kong, R., Ding, W., Lee, F.-H., Parker, Z., Kim, E., Learn, G. H., Hahn, P., Policicchio, B., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606636113 · Cited by 222
Reddy, V., Klein, C., Isenberg, D. A., Glennie, M. J., Cambridge, G., Cragg, M. S., & Leandro, M. J. (2017) · Rheumatology · doi:10.1093/rheumatology/kex067 · Cited by 205
“11 We next investigated the effect of Fc engineering on activation of NK cells using OBZ with wild-type glycosylation (OBZGly) and OBZ-PG LALA, which completely lacks FcγR engagement [43].”
BackgroundHigh‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responses
Pollara, J., Hart, L., Brewer, F., Pickeral, J., Packard, B. Z., Hoxie, J. A., Komoriya, A., Ochsenbauer, C., Kappes, J. C., Roederer, M., et al. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21084 · Cited by 202
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
Nimmerjahn, F., Lux, A., Albert, H., Woigk, M., Lehmann, C., Dudziak, D., Smith, P., & Ravetch, J. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014515107 · Cited by 200
Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles
Brown, E. P., Dowell, K. G., Boesch, A. W., Normandin, E., Mahan, A. E., Chu, T., Barouch, D. H., Bailey-Kellogg, C., Alter, G., & Ackerman, M. E. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.01.010 · Cited by 195
Wagh, K., Bhattacharya, T., Williamson, C., Robles, A., Bayne, M., Garrity, J., Rist, M., Rademeyer, C., Yoon, H., Lapedes, A., et al. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005520 · Cited by 191
“Second, because bnAbs can engage in Fc receptor-mediated effector functions [77, 78], the overall in vivo efficacy of bnAb combinations might be greater than the neutralization measured in vitro.”
Self-citationNK cells in HIV‐1 infection: evidence for their role in the control of HIV‐1 infection
Alter, G., & Altfeld, M. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02045.x · Cited by 187
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
Yamin, R., Jones, A. T., Hoffmann, H.-H., Schäfer, A., Kao, K. S., Francis, R. L., Sheahan, T. P., Baric, R. S., Rice, C. M., Ravetch, J. V., et al. (2021) · Nature · doi:10.1038/s41586-021-04017-w · Cited by 185
“Consistent with previous studies on other viral pathogens, including HIV-1 28 , influenza 24 and Ebola 29 , our findings suggest that FcγR—but not complement pathways—confer monoclonal antibody-mediated protection, as monoclonal antibodies lack protective activity in mice deficient for all classes…”
ResultInfluentialA Neutralizing Human Monoclonal Antibody Protects African Green Monkeys from Hendra Virus Challenge
Bossart, K. N., Geisbert, T. W., Feldmann, H., Zhu, Z., Feldmann, F., Geisbert, J. B., Yan, L., Feng, Y.-R., Brining, D., Scott, D., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002901 · Cited by 179
“4 inNHPs, it will be critical to establish acceptable therapeutic guidelines pertinent to either accidental or natural exposure to HeV.”
BackgroundThe Antibody Response against HIV-1
Overbaugh, J., & Morris, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007039 · Cited by 177
“…work through ADCC/ADCVI comes from passive immunization showing that a HIV-specific MAb engineered with decreased FcgR binding potential provided only partial protection compared to the original MAb, despite having similar neutralizing activity against the challenge virus (Hessell et al. 2007).”
BackgroundMoog, C., Dereuddre-Bosquet, N., Teillaud, J.-L., Biedma, M. E., Holl, V, Van Ham, G., Heyndrickx, L., Van Dorsselaer, A., Katinger, D., Vcelar, B., et al. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.23 · Cited by 158
“Involvement of Fc-mediated inhibition following human mAb transfer has been previously demonstrated by b12mutant LALA.3 Indeed, IgG1 from human or macaque origin showed identical FcgR interaction and ADCC effector function profile in both human and NHP cells.32 We further demonstrated that the Fc-mediated inhibitory a…”
BackgroundNonneutralizing Functional Antibodies: a New “Old” Paradigm for HIV Vaccines
Excler, J.-L., Ake, J., Robb, M. L., Kim, J. H., & Plotkin, S. A. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00230-14 · Cited by 114
Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys
Leabman, M. K., Meng, Y. G., Kelley, R. F., DeForge, L. E., Cowan, K. J., & Iyer, S. (2013) · mAbs · doi:10.4161/mabs.26436 · Cited by 110
Monoclonal antibodies for prophylactic and therapeutic use against viral infections
Both, L., Banyard, A. C., van Dolleweerd, C., Wright, E., Ma, J. K.-C., & Fooks, A. R. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.01.025 · Cited by 107
“However, when both complement and the FcRn (neonatal Fc receptor) were abolished, the same antibody showed reduced in vivo protective capacity [29].”
Engineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
Johnson, M. J., Laoharawee, K., Lahr, W. S., Webber, B. R., & Moriarity, B. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-30358-0 · Cited by 92
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.07.027 · Cited by 78
“Protection by antiviral neutralizing antibodies in animal models of influenza A and HIV-1 was shown to require the contribution of effector functions mediated by Fc-FcgR interactions for optimal efficacy (DiLillo et al., 2014; Hessell et al., 2007).”
HIV-1 cell-to-cell transmission and broadly neutralizing antibodies
Dufloo, J., Bruel, T., & Schwartz, O. (2018) · Retrovirology · doi:10.1186/s12977-018-0434-1 · Cited by 69
Gardner, M. R., Fetzer, I., Kattenhorn, L. M., Davis-Gardner, M. E., Zhou, A. S., Alfant, B., Weber, J. A., Kondur, H. R., Martinez-Navio, J. M., Fuchs, S. P., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.004 · Cited by 60
“animal models, raise the possibility that antibody effector functions might play an important role in preventing HIV-1 transmission.(19,20) Thus, antibodies with immunoglobulin G (IgG)1 Fc domains are generally used to study antibody-mediated prophylaxis.”
BackgroundAntiatherosclerotic Effect of an Antibody That Binds to Extracellular Matrix Glycosaminoglycans
Soto, Y., Acosta, E., Delgado, L., Pérez, A., Falcón, V., Bécquer, M. A., Fraga, Á., Brito, V., Álvarez, I., Griñán, T., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.238659 · Cited by 41
Cobey, S., Wilson, P., & Matsen, F. A. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0235 · Cited by 40
“Important discoveries have recently been made concerning the Fc region, including its potentially important role in HIV antibodies that were previously thought to operate by blocking viral entry [62,63].”
BackgroundBennett, M. R., Bombardi, R. G., Kose, N., Parrish, E. H., Nagel, M. B., Petit, R. A., Read, T. D., Schey, K. L., Thomsen, I. P., Skaar, E. P., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy635 · Cited by 29
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
Metadata
- Authors
- Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., Marx, P. A., & Burton, D. R.
- Venue
- Nature
- Published
- 2007-09
- Volume
- 449
- Issue
- 7158
- Pages
- 101-104
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2030129290
- Cited by
- 901
- References
- 21
- FWCI
- 16.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.